Highlights
KLSE: HARTA (5168)       HARTALEGA HOLDINGS BHD MAIN : Health Care
Last Price Today's Change   Day's Range   Trading Volume
5.91   +0.02 (0.34%)  5.83 - 5.92  279,000
Analyze this stock with MQ Trader system

Financials


Market Cap: 19,973 Million

Market Cap 19,973 Million
NOSH 3,379 Million

Latest Audited Result:  31-Mar-2017

Latest Audited Result: 31-Mar-2017
Announcement Date 31-Jul-2017
Next Audited Result: 31-Mar-2018
Est. Ann. Date: 31-Jul-2018
Est. Ann. Due Date: 27-Sep-2018

Latest Quarter:  31-Dec-2019 [#3]

Latest Quarter: 31-Dec-2019 [#3]
Announcement Date 11-Feb-2020
Next Quarter: 31-Mar-2020
Est. Ann. Date: 07-May-2020
Est. Ann. Due Date: 30-May-2020
QoQ | YoY   16.76%  |    1.27%

Annual (Unaudited) ( EPS: 13.50, P/E: 43.78 )

Revenue | NP to SH 2,827,879  |  456,204
RPS | P/RPS 83.68 Cent  |  7.06
EPS | P/E | EY 13.50 Cent  |  43.78  |  2.28%
DPS | DY | Payout % 8.37 Cent  |  1.42%  |  61.97%
NAPS | P/NAPS 0.66  |  8.96
YoY   3.83%
NP Margin | ROE 16.13%  |  20.47%
F.Y. | Ann. Date 31-Mar-2019  |  07-May-2019

T4Q Result ( EPS: 12.15, P/E: 48.65 )

Revenue | NP to SH 2,829,964  |  410,563
RPS | P/RPS 83.74 Cent  |  7.06
EPS | P/E | EY 12.15 Cent  |  48.65  |  2.06%
DPS | DY | Payout % 7.33 Cent  |  1.24%  |  60.36%
NAPS | P/NAPS 0.73  |  8.13
QoQ | YoY   0.37%  |    -14.73%
NP Margin | ROE 14.54%  |  16.72%
F.Y. | Ann. Date 31-Dec-2019  |  11-Feb-2020

Annualized Result ( EPS: 12.59, P/E: 46.93 )

Revenue | NP to SH 2,861,433  |  425,604
RPS | P/RPS 84.67 Cent  |  6.98
EPS | P/E | EY 12.59 Cent  |  46.93  |  2.13%
DPS | DY | Payout % -
NAPS | P/NAPS -
QoQ | YoY   7.51%  |    -12.51%
NP Margin | ROE 14.92%  |  17.33%
F.Y. | Ann. Date 31-Dec-2019  |  11-Feb-2020



Business Performance

Business Performance (By Quarter)

Trailing 4 Quarters Trailing 8 Quarters
Available Quarters 4 Quarters 8 Quarters
Continuous Quarters Of Revenue Growth 2 / 4 50.00% 2 / 8 25.00%
Total Positive Profit Years 4 / 4 100.00% 8 / 8 100.00%
Continuous Quarters Of Positive Profit 4 / 4 100.00% 8 / 8 100.00%
Continuous Quarters Of Profit Growth 3 / 4 75.00% 3 / 8 37.50%
Continuous Quarters Of Adjusted EPS Growth 3 / 4 75.00% 3 / 8 37.50%
Total Dividend Years 4 / 4 100.00% 8 / 8 100.00%
Continuous Quarters Of Dividend 4 / 4 100.00% 8 / 8 100.00%
Continuous Quarters Of Dividend Growth 1 / 4 25.00% 1 / 8 12.50%
Continuous Quarters Of Adjusted Dps Growth 1 / 4 25.00% 1 / 8 12.50%
Average ROE 4.38% 5.08%
Average Net Profit Margin 14.51% 16.01%

Business Performance (By Year)

Last 5 Financial Years Last 10 Financial Years
Available Years 5 Years 10 Years
Continuous Years Of Revenue Growth 5 / 5 100.00% 10 / 10 100.00%
Total Positive Profit Years 5 / 5 100.00% 10 / 10 100.00%
Continuous Years Of Positive Profit 5 / 5 100.00% 10 / 10 100.00%
Continuous Years Of Profit Growth 4 / 5 80.00% 4 / 10 40.00%
Continuous Years Of Adjusted EPS Growth 4 / 5 80.00% 4 / 10 40.00%
Total Dividend Years 5 / 5 100.00% 10 / 10 100.00%
Continuous Years Of Dividend 5 / 5 100.00% 10 / 10 100.00%
Continuous Years Of Dividend Growth 2 / 5 40.00% 2 / 10 20.00%
Continuous Years Of Adjusted Dps Growth 2 / 5 40.00% 2 / 10 20.00%
Average ROE 18.78% 31.35%
Average Net Profit Margin 17.10% 20.18%

Key Result

Key Result

T4Q Annualized Annual (Unaudited) Last 10 FY Average Last 5 FY Average
Revenue 2,829,964 2,861,433 2,827,879 1,407,668 1,939,937
NP to SH 410,563 425,604 456,204 264,649 329,152
Dividend 247,826 246,715 282,716 113,991 152,296
Adjusted EPS 12.15 12.59 13.50 7.83 9.74
Adjusted DPS 7.33 7.30 8.37 3.37 4.51

NP to SH = Net Profit Attributable to Shareholder, EPS = Earning Per Share, DPS = Dividend Per Share

All figures in '000 unless specified.

EPS & DPS's figures in Cent.


Growth

Growth (By Quarter)

LQ QoQ LQ YoY CQ YoY LQ vs Average of T4Q LQ vs Average of T8Q
Revenue 12.28% 10.11% 0.10% 12.59% 13.98%
NP to Owner 16.76% 1.27% -12.51% 18.15% 8.76%
Dividend 0.23% -17.20% -15.67% -2.26% -9.13%
Adj. EPS 16.76% 1.27% -12.51% 18.15% 8.76%
Adj. DPS 0.23% -17.20% -15.67% -2.26% -9.13%

LQ = Latest Quarter, CQ = Cumulative Quarter, T4Q = Trailing 4 Quarters, T8Q = Trailing 8 Quarters, QoQ = Quarter on Quarter, YoY = Year on Year

Growth (By Year)

T4Q vs LFY T4Q vs AL5FY T4Q vs AL10FY AQR vs LFY AQR vs AL5FY AQR vs AL10FY LFY YoY LFY vs AL5FY LFY vs AL10FY
Revenue 0.07% 45.88% 101.04% 1.19% 47.50% 103.27% 17.55% 45.77% 100.89%
NP to Owner -10.00% 24.73% 55.13% -6.71% 29.30% 60.82% 3.83% 38.60% 72.38%
Dividend -12.34% 62.73% 117.41% - % - % - % 22.16% 85.64% 148.02%
Adj. EPS -10.00% 24.73% 55.13% -6.71% 29.30% 60.82% 3.83% 38.60% 72.38%
Adj. DPS -12.34% 62.73% 117.41% - % - % - % 22.16% 85.64% 148.02%

T4Q = Trailing 4 Quarters, T8Q = Trailing 8 Quarters, AL5FY = Average of Last 5 Financial Years, AL10FY = Average of Last 10 Financial Years, LFY = Latest Financial Year AQR = Annualized Quarter Result, YoY = Year on Year

Trade this stock and receive a FREE I3investor T-shirt after 5 trades. Find out more.
  7 people like this.
 
yingkang87 Good quarter tomorrow Rm7
11/02/2020 6:02 PM
Fooksing Wong CONGRATS TO ALL :)
11/02/2020 6:20 PM
no buy no feel fuyoh if factor in Q1 corno virus result lagi bagus next quarter
11/02/2020 7:25 PM
itstime Anyone realise usually Harta every QR mentioned about they working on FDA approval. Suddenly this QR not mention anything about FDA...
11/02/2020 8:29 PM
stock_hunt got liao mai no need update lo...lol..wait to announce...hehe
11/02/2020 9:20 PM
gemfinder No surprise.. sell
11/02/2020 9:30 PM
kk7198 Just keep and not need to sell,just spend your quarterly dividend.
11/02/2020 9:51 PM
stanic88 As long as stays at rm6.00 until next quarter with 30% yoy improve, or 40% yoy growth consider good d.
12/02/2020 12:29 AM
Mabel Well done Malaysia.

18 millions contribution from the industry is very commendable..

Very proud to be associated with this company!

Happy to be on board together with her sister Top Gloves..

Meow..
12/02/2020 12:42 AM
mileskoon If you guys are looking for virus theme play, take a look at biohldg, it is one of the pharmacy and health supplement counter. The demand of vitamin and health supplement is increasing recently. Surprisingly, the share price is still trading at bottom, means the downside risk is limited, while upside risk is huge. It would rebound back it's fair value in near future. The beast is yet to wake up.
12/02/2020 7:09 AM
kk7198 @mileskoon, Harta is for long term as their management is cleaner...not like Topglove with Aspion saga and is far sighted like AMG which is getting approval from FDA in this year.Now is not virus theme play as the virus is peaking this month.
12/02/2020 7:25 AM
gemfinder New virus cases drop sgsin.. peak soon. Sell gloves
12/02/2020 7:28 AM
kk7198 Sell but make sure to collect back.
12/02/2020 8:13 AM
ov123 This is easily one of the best listed glove companies in Bursa.
12/02/2020 9:59 AM
learner35 1st timer buy share, should i buy some now or wait?
12/02/2020 10:34 AM
T1T4N Its not about the virus cases drop or what.
Whole world has HEALTH CONCIOUS UP LEVEL to MAXIMUM NOW.

Olympic 2020 is at JAPAN, the most affected country outside china.
Coming Euro2020 also (football)

Do you think the demand will DROP due to virus case turn better?

Think again.
12/02/2020 1:06 PM
Mabel Just buy and forget..
12/02/2020 2:13 PM
Chelsea Global glove demand surge where Malaysia order increase from 192B to 230B (additional 38B) which equivalent to half Top glove. This demand will continue grow due health concern awareness which arise from flu virus in US and COVID-19. As u can c, past 5 years the CAGR average is 12% compare with 7% on past decade. My target for Harta after include plant 6 is rm7 and plant 7 is rm7.8

CHELSEA
12/02/2020 2:17 PM
gggSTOCK TP 7 by end of the month
12/02/2020 3:14 PM
kenie New coronavirus vaccine may be faster to develop
KUALA LUMPUR (Feb 12): With the number of cases and deaths already surpassing that of SARS, teams around the world are racing to come up with a vaccine against the novel coronavirus (Covid-19).
At the time of writing, the virus has infected 45,194 people and killed 1,114 others.
Developing a vaccine safe for human use typically takes years, but there is reason to believe that the process will be speedier this time around, said academician and virologist Emeritus Prof Datuk Dr Lam Sai Kit.
“Advances in technology now makes it possible to come up with candidate vaccines in a matter of weeks, unlike traditional methods which can take years,” he told Bernama when contacted.
In addition to that, scientists in China sequenced the virus’s genome and made it available on Jan 10, just a month after the Dec 8 report of the first case of pneumonia from an unknown virus in Wuhan.
In contrast, scientists took more than half a year to sequence the SARS coronavirus after the outbreak began in late 2002.

How long will it take?
Lam noted that although candidate vaccines may be available in a matter of weeks, it would take much longer for them to be evaluated for human use.
“These candidate vaccines have to be tested in animal studies before human clinical trials can be started. It is still a long road ahead, and by the time a vaccine is ready, the outbreak may already be over — like in the case of SARS, where it took 20 months before a candidate vaccine was developed,” said Lam.
The vaccine never made it to the market because the virus was successfully contained with public health measures. The vaccine against MERS, meanwhile, is still being developed.
Immunologist Datuk Dr Musa Nordin said despite the pressure to come up with a vaccine as soon as possible, it must be noted that vaccine development remains an expensive and risky process.
“On average, it takes 10 years from pre-clinical trials through Phase 1-3 clinical trials before it is proven efficacious and safe for registration by regulatory bodies and use in man.
“However, the Covid-19 has the benefit of experience with previous candidate vaccines for MERS and SARS, allowing a jump start on the development of vaccines. If I had to hazard a best optimistic guess, I would say (a Covid-19 vaccine would be developed) within six months,” he said to Bernama.

What if it mutates?
One of the fears is that the Covid-19 would mutate after a vaccine is finally developed, affecting its efficacy.
However, it should be noted that Covid-19 does not undergo the same type of genome shuffling as the influenza virus, which is constantly mutating.
Like SARS, the genome of the Covid-19 comprises a single strand of RNA (ribonucleic acid). Microbes with such genome are known to mutate very quickly, but SARS has a molecular proofreading system that reduces its mutation rate.
Given the similarity to SARS at the genomic level, it has been suggested that the Covid-19 would not be as prone to mutation as the flu virus, which comprises multiple single-stranded RNA segments.
Therefore, if a vaccine is produced, it would still be effective.
Lam said that mutation is always a possibility with RNA viruses like the Covid-19.
“Usually, a major change happens when the virus jumps species. Hopefully, if there is a mutation, it will be a minor and not involving the spike protein, which is the important antigen used to produce the neutralising antibody in our immune system.
“With minor changes, the vaccine will still offer protection, or modify the severity of the disease,” he said.
CEPI
The Coalition of Endemic Preparedness Innovations (CEPI) in January announced that it would be funding three programmes to develop vaccines against the 2019-nCov.
It has engaged, among others, the Queensland University to work on a vaccine using its recently developed rapid response technology.
The university’s head of School of Chemistry and Molecular Biosciences Prof Paul Young said that they would be using the novel technology, known as the molecular clamp, for the rapid generation of the vaccine.
Young’s team of researchers have already experienced using this novel technology to produce candidate vaccines against influenza, Nipah, Ebola, and MERS. The team is optimistic that it will be able to develop the Covid-19 vaccine within six months.
“We are working around the clock to produce enough of the spike proteins in cells to produce this sub-unit vaccine,” said Young in an email.
A sub-unit vaccine is a fragment of a pathogen, typically a surface protein that is used to trigger an immune response. This in turn will stimulate acquired immunity against the pathogen from which it is derived.
CEPI is a non-profit organisation formed in 2017 to fund vaccine development for emerging infectious diseases. It is based in Oslo, Norway, and is a global partnership created to spearhead development
12/02/2020 3:34 PM
Alibaba Limskeong what happens to harta C28, mother up son go down, anyone know this.....?
12/02/2020 5:50 PM
James Ng https://klse.i3investor.com/blogs/general/2020-02-12-story-h1483791340.jsp
[转贴] [Facebook live video:浅谈Hartalega holdings bhd (Harta)] - James的股票投资James Share Investing
12/02/2020 9:28 PM
ching9 what happens to harta C28, mother up son go down, anyone know this.....? + 1
12/02/2020 5:50 PM

Same enquiry , Anyone possible reason to share?
12/02/2020 11:50 PM
gemfinder Virus peak liao. Sell gloves
13/02/2020 7:27 AM
James Ng https://klse.i3investor.com/blogs/general/2020-02-13-story-h1483791490.jsp
[转贴] [HARTALEGA HOLDINGS BHD:第六工厂的第一条生产线已于2020年1月投入使用,其余生产线将逐步投产,以满足不断增长的需求;一旦建成,第六工厂的年产量将达到47亿个] - James的股票投资James Share Investing
13/02/2020 7:53 AM
skybursa More than 14,000 new case & death over 280
13/02/2020 8:21 AM
skybursa 242 reported death
13/02/2020 8:24 AM
cheeseburger looking at spiking up confirmed case hit 60k, is very unlikely the demand for gloves not follow suit. It will only go up not come down. The stock analysis really need do homework before you call it too expensive. It is reasonable with much higher demand flooding the counter.
13/02/2020 9:04 AM
chl1989 it will go back to rm7 very soon
13/02/2020 12:21 PM
Jerichomy Pls dont accumulate now, my friend in adventa and ocncash told me that banker oredi left all the mask and glove counter...they are in steel counters...pls feel free to join them
13/02/2020 9:48 PM
JunJun left? it has barely begun
13/02/2020 9:56 PM
meistsk3134 rm7 next year
13/02/2020 10:30 PM
Chelsea lol Jerichomy don't listen to others. Please refer to the top 20 fund as closing 31 January 2020 where mostly new fund enter except Supermax.
14/02/2020 2:20 PM
gggSTOCK dont listen to those stupid analyst, they got paid even if they write rubbish
14/02/2020 5:06 PM
Rf888 Dont simply listen of analyst, please go do your own homework. Now china urgent need glove, next quarter result is very important. Please go study the result, you will get hint inside.

In line with growing rubber glove demand globally, Hartalega will continue with its NGC
capacity expansion plans. First line of Plant 6 was commissioned in January 2020 with
remaining production lines to come on stream progressively to cater for the rising demand.
Plant 6 will have an annual installed capacity of 4.7 billion pieces once completed. Plant 7 is
also in the expansion pipeline catering to small orders, focusing more on specialty products
and will have an annual installed capacity of 3.4 billion pieces. With the progressive
commissioning of Plant 6 and 7, Hartalega’s annual installed capacity is expected to increase
from the current 36.6 billion to 44.7 billion pieces by FY2022.
15/02/2020 1:50 PM
Rf888 The virus will effect many industries, only glove counter is super safe now and the fundamental is super good compare with others industry. This is the time, see back the H1N1 time how the glove counter result? Dont simply sell out your glove counter, is time to win big.
15/02/2020 1:53 PM
Rf888 When ppl scare, you need brave.
15/02/2020 1:54 PM
probability no of new confirmed infections per day had been clearly dropping....:

5th Feb: 3927
6th Feb: 3723
7th Feb: 3163
8th Feb: 3437
9th Feb: 2676
10th Feb: 3001
11th Feb: 2546
12th Feb: 1970
13th Feb: 1819
14th Feb: 1995
15th Feb: 1500

...........

90% of the above cases was in Hubei only, meaning only about 200 confirmed cases in China outside Hubei.

I think the war on the virus internationally is over.

what more today OUTSIDE China:

ONLY 1 CASE reported!
....................
15/02/2020 1:55 PM
Rf888 You can imagine how big 14 billion people china market?
15/02/2020 2:04 PM
probability may be can market in hubei only now...outside hubeis is only 200 confirmed cases per day...

even hubei will be completely under control in a month
15/02/2020 2:04 PM
Rf888 The real amount and you get the report amount at internet is big different, of course also hope this virus can get vaccine early.
15/02/2020 2:37 PM
gggSTOCK break 6.20 today then it will fly
17/02/2020 9:36 AM
hotmission fly down south...
19/02/2020 10:03 AM
chl1989 rm7 buy
19/02/2020 10:06 AM
sathishfiles 5.9 going down ??
19/02/2020 11:03 AM
yoyo Glove counters heat should b over concurrently with the dropping rate of virus infected cases. Harta TP RM5.20
19/02/2020 12:16 PM
WanUtama2015 Rf888, the China population is 1.4 billion ( 14亿 or 1400 million ), not 14 billion.
19/02/2020 3:32 PM
Gtrade yesterday new Covid-19 cases drop to 359. good sign but with 1400m China workforce and masses back to work, or released from quarantine, any sparks new clusters would swing the authority in panic mode again. This time it may even be too widespread to manage.For the next 6 monhs, heightened demand for gloves ,and hygien equipment will continue
20/02/2020 12:59 PM
ttluck no need worry la.....glove stock quite stable altough virus gone with the wind...hehe....looking longer term
20/02/2020 5:41 PM
presswood True, nx QR sure big green, epf will buy back after dividen, everywhere using glove, why worried
20/02/2020 7:49 PM